Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms.
Read More…
Industry, Sector and Symbol
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees10,000
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable
Zoetis (NYSE:ZTS) Frequently Asked Questions
What is Zoetis' stock symbol?
Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."
How often does Zoetis pay dividends? What is the dividend yield for Zoetis?
Zoetis announced a quarterly dividend on Tuesday, February 11th. Shareholders of record on Friday, April 17th will be paid a dividend of $0.20 per share on Monday, June 1st. This represents a $0.80 annualized dividend and a yield of 0.55%. The ex-dividend date of this dividend is Thursday, April 16th. View Zoetis' Dividend History.
How will Zoetis' stock buyback program work?
Zoetis announced that its Board of Directors has approved a stock buyback plan on Wednesday, December 12th 2018, which authorizes the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 4.7% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's leadership believes its stock is undervalued.
How were Zoetis' earnings last quarter?
Zoetis Inc (NYSE:ZTS) released its quarterly earnings results on Thursday, February, 13th. The company reported $0.92 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.88 by $0.04. The company had revenue of $1.67 billion for the quarter, compared to analysts' expectations of $1.64 billion. The company's revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.79 EPS. View Zoetis' Earnings History.
When is Zoetis' next earnings date?
What guidance has Zoetis issued on next quarter's earnings?
Zoetis issued an update on its FY20 earnings guidance on Thursday, February, 13th. The company provided earnings per share guidance of $3.90-4.00 for the period, compared to the Thomson Reuters consensus estimate of $4.01. The company issued revenue guidance of $6.65-6.80 billion, compared to the consensus revenue estimate of $6.69 billion.
What price target have analysts set for ZTS?
16 Wall Street analysts have issued 1 year price objectives for Zoetis' stock. Their forecasts range from $105.00 to $160.00. On average, they anticipate Zoetis' stock price to reach $135.07 in the next twelve months. This suggests that the stock has a possible downside of 6.3%. View Analyst Price Targets for Zoetis.
What is the consensus analysts' recommendation for Zoetis?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 7 hold ratings, 7 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zoetis.
Has Zoetis been receiving favorable news coverage?
Headlines about ZTS stock have trended somewhat positive on Monday, according to InfoTrie. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Zoetis earned a news impact score of 2.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Zoetis.
Are investors shorting Zoetis?
Zoetis saw a decline in short interest in January. As of January 31st, there was short interest totalling 5,190,000 shares, a decline of 12.6% from the January 15th total of 5,940,000 shares. Based on an average trading volume of 2,140,000 shares, the short-interest ratio is presently 2.4 days. Approximately 1.1% of the shares of the stock are short sold. View Zoetis' Current Options Chain.
Who are some of Zoetis' key competitors?
Some companies that are related to Zoetis include AbbVie (ABBV), The Medicines (MDCO), Assembly Biosciences (ASMB), Ampio Pharmaceuticals (AMPE), Melinta Therapeutics (MLNT), Acura Pharmaceuticals (ACUR), Akorn (AKRX), Allergan (AGN), BioDelivery Sciences International (BDSI), Bristol-Myers Squibb (BMY), Corcept Therapeutics (CORT), Cumberland Pharmaceuticals (CPIX), Eli Lilly And Co (LLY), Endo International (ENDP) and Horizon Therapeutics (HZNP).
What other stocks do shareholders of Zoetis own?
Who are Zoetis' key executives?
Zoetis' management team includes the folowing people:
- Mr. Juan Ramón Alaix, CEO & Director (Age 68)
- Mr. Glenn C. David, Exec. VP & CFO (Age 47)
- Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 58)
- Mr. Clinton A. Lewis Jr., EVP and Grp Pres of Intl. Ops., Comm. Devp., Glbl Genetics, Aquatic Health & Human Medical Digs (Age 52)
- Ms. Kristin C. Peck, Exec. VP and Group Pres of U.S. Operations, Bus. Devel. & Strategy (Age 48)
Who are Zoetis' major shareholders?
Zoetis' stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (4.17%), FMR LLC (2.45%), Polen Capital Management LLC (2.27%), Massachusetts Financial Services Co. MA (1.67%), Sands Capital Management LLC (1.17%) and UBS Asset Management Americas Inc. (1.06%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Institutional Ownership Trends for Zoetis.
Which major investors are selling Zoetis stock?
ZTS stock was sold by a variety of institutional investors in the last quarter, including Sonora Investment Management LLC, FMR LLC, Cantillon Capital Management LLC, Artemis Investment Management LLP, Renaissance Technologies LLC, Eaton Vance Management, Lord Abbett & CO. LLC and Bank of New York Mellon Corp. Company insiders that have sold Zoetis company stock in the last year include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Insider Buying and Selling for Zoetis.
Which major investors are buying Zoetis stock?
ZTS stock was bought by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Goldman Sachs Group Inc., Milestone Resources Group Ltd, Marshall Wace LLP, Credit Suisse AG, UBS Group AG, Massachusetts Financial Services Co. MA and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for Zoetis.
How do I buy shares of Zoetis?
Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Zoetis' stock price today?
One share of ZTS stock can currently be purchased for approximately $144.17.
MarketBeat Community Rating for Zoetis (NYSE ZTS)
MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe ZTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
